Mvalve is developing technology to treat mitral valve regurgitation, according to its LinkedIn profile. Co-founder & CEO Assif Stoffman is an executive vice president with Israeli venture capital fund XT Hitech, which is the sole investor in Mvalve, according to Globes.
The Boston Scientific investment is a $15 million convertible debt offering, according to the newspaper, which cited unnamed sources.
Mvalve has filed 3 patent applications, 2 covering "Cardiac Valve Support Structure" and another covering "Cardiac Valve Modification Device," according to PatentBuddy.
Stealthy Mvalve has a single-page website listing only its name, an owner login and the slogan "A paradigm shift in the treatment of mitral regurgitation." Its device is designed to support the mitral valve rather than replace it, according to Globes.